S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NYSE:ZTS

Zoetis (ZTS) Stock Forecast, Price & News

$171.12
-0.76 (-0.44%)
(As of 06/5/2023 ET)
Compare
Today's Range
$170.01
▼
$172.66
50-Day Range
$161.00
▼
$186.23
52-Week Range
$124.15
▼
$187.82
Volume
1.50 million shs
Average Volume
2.06 million shs
Market Capitalization
$79.08 billion
P/E Ratio
38.63
Dividend Yield
0.88%
Price Target
$221.14
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Zoetis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
29.2% Upside
$221.14 Price Target
Short Interest
Healthy
0.80% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-4.66
Upright™ Environmental Score
News Sentiment
0.88mentions of Zoetis in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$763,228 Sold Last Quarter
Proj. Earnings Growth
10.56%
From $5.40 to $5.97 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.86 out of 5 stars

Medical Sector

32nd out of 985 stocks

Pharmaceutical Preparations Industry

12th out of 487 stocks

See Top Rated MarketRank™ Stocks Here

ZTS stock logo

About Zoetis (NYSE:ZTS) Stock

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S. market and regulatory activities. The International segment includes non-U.S. market and regulatory activities. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Stock News Headlines

May 18, 2023 | marketbeat.com
Zoetis Declares New Dividend, Hinting At Undervaluation (ZTS)
Zoetis shareholders woke up to news of JAB's acquisition of Pumpkin, a per insurance platform where Zoetis owns a minority stake. 2023 outlooks suggest a rally
June 4, 2023 | finance.yahoo.com
Zoetis' (NYSE:ZTS) five-year earnings growth trails the strong shareholder returns
June 5, 2023 | Behind the Markets (Ad)
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
June 2, 2023 | americanbankingnews.com
Critical Analysis: Zoetis (NYSE:ZTS) vs. Tyra Biosciences (NASDAQ:TYRA)
May 30, 2023 | finance.yahoo.com
Zoetis to Participate in the Stifel 2023 Jaws and Paws Conference
May 29, 2023 | benzinga.com
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,000 Today
May 28, 2023 | americanbankingnews.com
Analysts Set Zoetis Inc. (NYSE:ZTS) PT at $221.14
May 28, 2023 | americanbankingnews.com
Analysts Set Zoetis Inc. (NYSE:ZTS) Target Price at $221.14
June 5, 2023 | Behind the Markets (Ad)
Why did Biden repeal Trump's Executive Order?!
" Why did Biden repeal Trump's Executive Order?! Within 10 days of taking office, President Trump signed "Executive Order 13771" in an effort to win the battle for what 60 minutes said could be "the most consequential discovery in biomedicine this century." So why did Biden repeal this? Click here to learn more >>> "
May 26, 2023 | msn.com
Atlantic Equities Reiterates Zoetis Inc - (ZTS) Overweight Recommendation
May 25, 2023 | cnbc.com
Zoetis CEO Kristin Peck sits down with Jim Cramer
May 25, 2023 | finance.yahoo.com
Zoetis Holds Investor Day and Presents Strategy to Shape Animal Health for the Next Decade
May 21, 2023 | fool.com
Zoetis (NYSE: ZTS)
May 19, 2023 | americanbankingnews.com
Zoetis (NYSE:ZTS) Now Covered by Analysts at StockNews.com
May 18, 2023 | finance.yahoo.com
Multiple Reasons for the Outperformance of Zoetis (ZTS)
May 16, 2023 | businesswire.com
JAB’s Pet Insurance Platform Acquires Pumpkin, Expanding its Global Leadership in the Fast-Growing Pet Insurance Industry
May 15, 2023 | msn.com
Zoetis's Return On Capital Employed Overview
May 13, 2023 | msn.com
Zoetis Inc - (ZTS) Declares $0.38 Dividend
May 11, 2023 | msn.com
Zoetis declares $0.375 dividend
May 11, 2023 | msn.com
Here's How Much $100 Invested In Zoetis 10 Years Ago Would Be Worth Today
May 11, 2023 | finance.yahoo.com
Zoetis Declares Third Quarter 2023 Dividend
May 11, 2023 | americanbankingnews.com
Zoetis (NYSE:ZTS) Price Target Lowered to $210.00 at Piper Sandler
May 10, 2023 | msn.com
Zoetis' Dividend Growth: Small Yield, Big Returns
May 9, 2023 | finance.yahoo.com
Zoetis Shares Are Barking Up the Right Tree
May 9, 2023 | americanbankingnews.com
Zoetis Inc. to Post Q2 2023 Earnings of $1.32 Per Share, William Blair Forecasts (NYSE:ZTS)
May 8, 2023 | markets.businessinsider.com
Piper Sandler Reaffirms Their Buy Rating on Zoetis (ZTS)
May 8, 2023 | markets.businessinsider.com
Zoetis' Osteoarthritis Med for Dogs Set to Deliver Significant Advantages In 2024, Analyst Says
See More Headlines

ZTS Price History

ZTS Company Calendar

Ex-Dividend for 6/1 Dividend
4/20/2023
Last Earnings
5/04/2023
Dividend Payable
6/01/2023
Today
6/05/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:ZTS
CUSIP
98978V10
CIK
1555280
Web
www.zoetis.com
Phone
(973) 822-7000
Fax
302-655-5049
Employees
13,800
Year Founded
2012

Price Target and Rating

Average Stock Price Forecast
$221.14
High Stock Price Forecast
$260.00
Low Stock Price Forecast
$180.00
Forecasted Upside/Downside
+29.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$4.43
Trailing P/E Ratio
38.70
Forward P/E Ratio
31.75
P/E Growth
2.78
Net Income
$2.11 billion
Net Margins
25.59%
Pretax Margin
32.44%
Return on Equity
50.26%
Return on Assets
16.24%

Debt

Debt-to-Equity Ratio
1.46
Current Ratio
3.27
Quick Ratio
1.94

Sales & Book Value

Annual Sales
$8.08 billion
Price / Sales
9.81
Cash Flow
$5.91 per share
Price / Cash Flow
29.00
Book Value
$9.45 per share
Price / Book
18.14

Miscellaneous

Outstanding Shares
462,110,000
Free Float
461,419,000
Market Cap
$79.23 billion
Optionable
Optionable
Beta
0.77

Social Links


Key Executives

  • Kristin C. PeckKristin C. Peck
    Chief Executive Officer & Director
  • Roxanne LaganoRoxanne Lagano
    Chief Human Resources Officer & Executive VP
  • Wetteny Joseph
    CFO, EVP & Head-Business Development
  • Mike McFarland
    Chief Medical Officer & Executive Vice President
  • Robert J. Polzer
    President-Research & Development, Executive VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ZTS Stock - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings or view top-rated stocks.

What is Zoetis' stock price forecast for 2023?

8 brokers have issued 12 month target prices for Zoetis' stock. Their ZTS share price forecasts range from $180.00 to $260.00. On average, they predict the company's stock price to reach $221.14 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price.
View analysts price targets for ZTS or view top-rated stocks among Wall Street analysts.

How have ZTS shares performed in 2023?

Zoetis' stock was trading at $146.55 at the start of the year. Since then, ZTS stock has increased by 16.8% and is now trading at $171.13.
View the best growth stocks for 2023 here.

Are investors shorting Zoetis?

Zoetis saw a drop in short interest in May. As of May 15th, there was short interest totaling 3,710,000 shares, a drop of 18.5% from the April 30th total of 4,550,000 shares. Based on an average daily trading volume, of 1,830,000 shares, the short-interest ratio is currently 2.0 days. Approximately 0.8% of the shares of the company are short sold.
View Zoetis' Short Interest.

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ZTS earnings forecast.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) posted its quarterly earnings data on Thursday, May, 4th. The company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. The company had revenue of $2 billion for the quarter, compared to analysts' expectations of $2.02 billion. Zoetis had a trailing twelve-month return on equity of 50.26% and a net margin of 25.59%. The company's revenue for the quarter was up .7% on a year-over-year basis. During the same period in the prior year, the company posted $1.32 EPS.
Read the conference call transcript.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Thursday, May 11th. Shareholders of record on Friday, July 21st will be given a dividend of $0.375 per share on Friday, September 1st. This represents a $1.50 annualized dividend and a dividend yield of 0.88%. The ex-dividend date of this dividend is Thursday, July 20th.
Read our dividend analysis for ZTS.

What ETFs hold Zoetis' stock?

ETFs with the largest weight of Zoetis (NYSE:ZTS) stock in their portfolio include ProShares Pet Care ETF (PAWZ), VanEck Agribusiness ETF (MOO), IQ Winslow Focused Large Cap Growth ETF (IWFG), SPDR S&P Pharmaceuticals ETF (XPH), iShares U.S. Pharmaceuticals ETF (IHE), VanEck Pharmaceutical ETF (PPH), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.50 per share and currently has a dividend yield of 0.87%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 33.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 25.13% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of $5.34-$5.44 for the period, compared to the consensus estimate of $5.40. The company issued revenue guidance of $8.57 billion-$8.72 billion, compared to the consensus revenue estimate of $8.65 billion.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.63%), State Street Corp (4.20%), Wellington Management Group LLP (2.60%), Price T Rowe Associates Inc. MD (2.22%), Geode Capital Management LLC (2.11%) and FMR LLC (1.74%). Insiders that own company stock include Catherine A Knupp, Glenn David, Gregory Norden, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $171.13.

How much money does Zoetis make?

Zoetis (NYSE:ZTS) has a market capitalization of $79.08 billion and generates $8.08 billion in revenue each year. The company earns $2.11 billion in net income (profit) each year or $4.43 on an earnings per share basis.

How many employees does Zoetis have?

The company employs 13,800 workers across the globe.

Does Zoetis have any subsidiaries?
The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Limited, Abaxis Europe GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma Animal Health Company, Alpharma Animal Health Hong Kong Co. Limited, Alpharma Bermuda LLC, Alpharma Euro Holdings LLC, Alpharma Holdings Barbados SRL, Alpharma LLC, Alpharma Luxembourg S.A.R.L. y Compania Limitada, Alpharma do Brasil Ltda., Bovigen, Catapult Genetics Pty Ltd, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Fish Vet Group, Fish Vet Group Limited, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Jorox Pty, King Animal Health, Microtek International Inc, Mikjan Corporation, Nexvet, Nexvet Australia Pty Ltd, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Performance Livestock Analytics Inc., Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS., Pharmaq Analytiq AS, Pharmaq Analytiq Limited, Pharmaq Analytiq SpA, Pharmaq Fishteq AS, Pharmaq Fishteq SpA, Pharmaq Ltd, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Phoenix Lab, Platinum Performance, Platinum Performance Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics Corporation, Synbiotics LLC, Vetnex Animal Health Ltd, Virtual Recall, Virtual Recall Limited, Virtual Recall Pty Ltd, ZNLabs, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis Animal Health ApS, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark ApS, Zoetis Deutschland GmbH, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management Shanghai Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis Import Egypt LLC, Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Reference Laboratories China Co. Ltd., Zoetis Reference Labs LLC, Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa Pty Ltd., Zoetis Spain S.L., Zoetis Subsidiary Holdings Inc., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Sweden AB, Zoetis Taiwan Limited, Zoetis Thailand Limited, Zoetis Treasury Center BV, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More
How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The official website for the company is www.zoetis.com. The company can be reached via phone at (973) 822-7000, via email at steve.frank@zoetis.com, or via fax at 302-655-5049.

This page (NYSE:ZTS) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -